Cerity Partners LLC Buys 7,235 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Cerity Partners LLC lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 63.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,630 shares of the company's stock after buying an additional 7,235 shares during the quarter. Cerity Partners LLC's holdings in IDEXX Laboratories were worth $7,824,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of IDXX. Geode Capital Management LLC raised its stake in IDEXX Laboratories by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock worth $948,279,000 after purchasing an additional 37,734 shares during the period. Bamco Inc. NY increased its holdings in shares of IDEXX Laboratories by 4.3% in the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock valued at $829,163,000 after acquiring an additional 82,264 shares during the last quarter. Invesco Ltd. increased its holdings in shares of IDEXX Laboratories by 6.8% in the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock valued at $479,999,000 after acquiring an additional 74,324 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of IDEXX Laboratories by 58.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company's stock worth $472,865,000 after purchasing an additional 414,802 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $412,258,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director owned 1,801 shares in the company, valued at approximately $922,724.34. The trade was a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock traded down $3.14 during mid-day trading on Friday, reaching $515.57. The stock had a trading volume of 69,581 shares, compared to its average volume of 642,543. The firm's 50 day simple moving average is $523.12 and its 200 day simple moving average is $462.00. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $549.52. The firm has a market cap of $41.46 billion, a PE ratio of 47.70, a P/E/G ratio of 3.80 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The company had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same period in the prior year, the company posted $2.71 EPS. The company's revenue was up 3.6% compared to the same quarter last year. On average, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on IDXX. Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They set a "buy" rating and a $625.00 target price for the company. Morgan Stanley raised their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Leerink Partners raised their target price on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday. Wall Street Zen upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Saturday, July 12th. Finally, Stifel Nicolaus raised their price target on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the stock a "hold" rating in a report on Wednesday, July 2nd. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $560.33.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.